With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

The detection of lumpy skin disease in Japan could be the game changer that prompts far greater financial investment into ...

“Arcturus is actively engaged with the U.S. government to prepare for the next pandemic, and clearance to proceed into the clinic with our STARR® self-amplifying mRNA technology is a key step in this ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

Arcturus Therapeutics (ARCT) Holdings announced that the U.S. Food and Drug Administration has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug application, ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...